Tuberculosis vaccine with improved efficacy

Details for Australian Patent Application No. 2004232485 (hide)

Owner Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.

Inventors Raupach, Barbel; Grode, Leander; Kaufmann, Stefan H. E.; Hess, Jurgen

Agent Davies Collison Cave

Pub. Number AU-B-2004232485

PCT Pub. Number WO2004/094469

Priority 60/464,644 23.04.03 US

Filing date 23 April 2004

Wipo publication date 4 November 2004

Acceptance publication date 26 November 2009

International Classifications

C07K 14/35 (2006.01) Peptides having more than 20 amino acids

C07K 14/195 (2006.01) Peptides having more than 20 amino acids - from bacteria

A61K 39/00 (2006.01) Medicinal preparations containing antigens or antibodies

Event Publications

1 December 2005 PCT application entered the National Phase

  PCT publication WO2004/094469 Priority application(s): WO2004/094469

26 November 2009 Application Accepted

  Published as AU-B-2004232485

25 March 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004232487-Method for identifying an antistreptococcal agent and its use for treating streptococcal infections

2004232484-5-hydroxyindoles with N-oxide groups and use thereof as a phosphodiesterase 4 inhibitor